Infectious Disease

Dermatology

Questions discussed in this category

Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?

2 Answers available

What is your preferred oral regime with duration for treatment of onychomycosis?

How frequently can you repeat the oral course?

4 Answers available

What approaches can we take to initiate therapy and improve survival rates in patients with HLH?

2 Answers available

What oral treatment options would you offer a patient with severe onychomycosis who is also on methotrexate for another condition?

2 Answers available

How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?

Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?

1 Answer available

What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?

1 Answer available

Is there a role for empiric scabies treatment in itchy patients without clear clinical signs of scabies?

Do you empirically treat itchy patients -with a non specific rash- for scabies without obvious clinical findings for scabies?

5 Answers available

For how long would you treat Klebsiella aerogenes folliculitis of the face manifesting as a cystic lesion?

Would you combine antibiotics with isotretinoin?

2 Answers available

Do you recommend testing for HPV in patients with oral lichen planus?

2 Answers available

Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?

1 Answer available

What topical or oral treatments do you recommend for patients with recurrent MRSA infections?

Do you recommend any changes to their personal hygiene practices? or changes to their environment?

1 Answer available

How do you approach patients with onychomycosis that does not respond to terbinafine and prolonged courses of fluconazole?

Would you switch to itraconazole or perform fungal cultures? When would you consider repeating the course of treatment?

2 Answers available

How do you think about biologic use in patients with underlying HIV infection?

2 Answers available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?

1 Answer available

Papers discussed in this category

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008-10

Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.

Clin Rheumatol, 2006 Dec 21

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 24

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).

Journal of fungi (Basel, Switzerland), 2019 Sep 04

A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis.

Infectious Disease

Dermatology

Questions discussed in this category

Papers discussed in this category

Related Topics in Infectious Disease